EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective

Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.

More from Archive

More from Pink Sheet